• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BCL2 Gene Record

  • Summary
  • Interactions
  • Claims
  • BCL2 596 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    596
    BCL2, APOPTOSIS REGULATOR
    BCL2
    Bcl-2
    PPP1R50
    151430
    990
    ENSG00000171791
    OTTHUMG00000132791
    P10415
    BCL2_HUMAN
    APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415]
    Apoptosis regulator Bcl-2
    PA25302
    BCL2 apoptosis regulator
    T31309
    59

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Interpro Name Apoptosis regulator, Bcl-2, BH
    Uniprot Status Swiss-Prot
    Interpro Short Name Bcl2_BH
    Interpro Acc IPR000712
    Target Class other
    Target Subclass regulator of apoptosis
    Target Subclass Other
    Transmembrane Helix Count 1
    Target Main Class Other
    Gene Biotype PROTEIN_CODING
    (16 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Kuo et al., 1999, Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis., Mol. Pharmacol.
    Osterreicher et al., 2001, Apoptosis and bcl-2 expression in irradiated lungs and the effect of pentoxifylline., Acta Medica (Hradec Kralove)
    Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
    Abulwerdi FA et al., 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation., J Med Chem
    Ran et al., 2005, [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]., Di Yi Jun Yi Da Xue Xue Bao
    Salleh et al., 2004, Gene expression profiling of p53(+/-) knockout and wild-type mice following diethylstilbestrol administration., IUBMB Life
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
    Pérez-Galán P et al., 2007, The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak., Blood
    Li J et al., 2008, A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells., Cancer Chemother Pharmacol
    Davids et al., 2013, ABT-199: taking dead aim at BCL-2., Cancer Cell
    Souers et al., 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets., Nat. Med.
    Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica
    Birkinshaw RW et al., 2019, Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations., Nat Commun
    Blombery P et al., 2020, Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax., Blood
    Lucas F et al., 2020, Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations., Blood
    Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov
    Blombery P et al., 2019, Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma., Br J Haematol
    King AC et al., 2017, Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies., Ann Pharmacother
    Mueller et al., 2003, Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer., Cancer Res.
    Baltaci et al., 2001, P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours., BJU Int.
    Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.
    Fisher et al., 1993, bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways., Cancer Res.
    Peters et al., 2000, Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed., Eur. J. Cancer
    Yoshino et al., 2006, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy., Clin. Cancer Res.
    Matsuyoshi et al., 2006, Bcl-2 phosphorylation has pathological significance in human breast cancer., Pathobiology
    Gan et al., 2006, Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors., Pharm. Res.
    Thomadaki et al., 2006, Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS., Biol. Chem.
    Zhang et al., 2007, Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells., Int. J. Cancer
    Ng et al., 2000, Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines., Anal. Quant. Cytol. Histol.
    Chi et al., 2001, A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer., Clin. Cancer Res.
    Heaton et al., 2004, Vitamin E amelioration of ethanol neurotoxicity involves modulation of apoptotis-related protein levels in neonatal rat cerebellar granule cells., Brain Res. Dev. Brain Res.
    Petrylak, 2005, Chemotherapy for androgen-independent prostate cancer., World J Urol
    Marshall et al., 2004, A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors., Ann. Oncol.
    Inoue et al., 2005, Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer., Oncol. Rep.
    Miyoshi et al., 2005, [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]., Nippon Rinsho
    Gligorov et al., 2004, Preclinical pharmacology of the taxanes: implications of the differences., Oncologist
    Magi-Galluzzi et al., 2007, Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study., Cancer
    Lin et al., 2006, In vitro folate deficiency induces apoptosis by a p53, Fas (Apo-1, CD95) independent, bcl-2 related mechanism in phytohaemagglutinin-stimulated human peripheral blood lymphocytes., Br. J. Nutr.
    Loberg RD et al., 2007, In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration., Neoplasia
    Shaker OG et al., 2011, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients., Clin Chim Acta
    Panasiuk et al., 2005, [The apoptosis of hepatic tissues in hepatitis C]., Przegl Epidemiol
    Anatol et al., 2005, Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy., World J. Gastroenterol.
    Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.
    Lin et al., 2005, Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells., Cancer Lett.
    Malugin et al., HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function., Mol. Pharm.
    Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem
    Jesmin et al., 2006, Effects of dual endothelin receptor antagonist on antiapoptotic marker Bcl-2 expression in streptozotocin-induced diabetic rats., Exp. Biol. Med. (Maywood)
    Serafin et al., Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines., Urol. Oncol.
    Chow et al., 2003, The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells., Breast Cancer Res. Treat.
    Tetè et al., 1999, The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin., Minerva Stomatol
    Piattelli et al., 1999, bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study., Oral Oncol.
    Ballestrero et al., 2004, Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells., Clin. Cancer Res.
    Emir et al., 2005, Beneficial effect of methylprednisolone on cardiac myocytes in a rat model of severe brain injury., Tohoku J. Exp. Med.
    Adişen et al., 2006, The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis., J Eur Acad Dermatol Venereol
    Weller et al., 1998, Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses., Int. J. Cancer
  • OBLIMERSEN   BCL2

    Interaction Score: 4.31

    Interaction Types & Directionality:
    antisense oligonucleotide (inhibitory)

    Interaction Info:
    Trial Name Genasense
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial TTD

  • BEAUVERICIN   BCL2

    Interaction Score: 2.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16297711


    Sources:
    NCI

  • VENETOCLAX   BCL2

    Interaction Score: 1.7

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor
    Direct Interaction yes

    PMIDs:
    23410971 23291630 31004028 31160589 31951646 32232486 30514704 31234236 28056525


    Sources:
    MyCancerGenome ChemblInteractions CIViC TTD

  • PROTUBOXEPIN A   BCL2

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22595423


    Sources:
    DTC

  • OBATOCLAX   BCL2

    Interaction Score: 1.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name obatoclax, GX15-070
    Novel drug target Established target

    PMIDs:
    17227835 17505826


    Sources:
    TALC TdgClinicalTrial TTD

  • ISOSORBIDE   BCL2

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name AT-101
    Novel drug target Established target

    PMIDs:
    18084610


    Sources:
    TdgClinicalTrial

  • HYPOXANTHINE   BCL2

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16611376


    Sources:
    NCI

  • TESETAXEL   BCL2

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name tesetaxel
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • ANG1005   BCL2

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ANG1005
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • NAVITOCLAX   BCL2

    Interaction Score: 0.6

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor
    Notes

    PMIDs:
    24749893


    Sources:
    TALC DTC ChemblInteractions TTD

  • CILENGITIDE   BCL2

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12154028


    Sources:
    NCI

  • MILATAXEL   BCL2

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name milataxel, MAC-321
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • RALTITREXED   BCL2

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10785598


    Sources:
    NCI

  • ISOTRETINOIN   BCL2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10638174 10621853


    Sources:
    NCI

  • TENIPOSIDE   BCL2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9842975


    Sources:
    NCI

  • ORTATAXEL   BCL2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ortataxel
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • TAZAROTENE   BCL2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16109552


    Sources:
    NCI

  • METHYLPREDNISOLONE   BCL2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16141680 16684279


    Sources:
    NCI

  • EDARAVONE   BCL2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ESTRAMUSTINE   BCL2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15869997


    Sources:
    NCI

  • VITAMIN E   BCL2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15158075


    Sources:
    NCI

  • OBATOCLAX MESYLATE   BCL2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • RIBAVIRIN   BCL2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21159314 16190549 15902734


    Sources:
    NCI PharmGKB

  • PHENYLBUTANOIC ACID   BCL2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10696460


    Sources:
    NCI

  • FLOXURIDINE   BCL2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8324744


    Sources:
    NCI

  • HYDROQUINONE   BCL2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10220568


    Sources:
    NCI

  • DOCETAXEL   BCL2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name BIND-014
    Novel drug target Established target
    Trial Name Docetaxel

    PMIDs:
    23963862 15685445 15277270 15643508 15714982 15161985 17674353


    Sources:
    TdgClinicalTrial PharmGKB

  • PACLITAXEL   BCL2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Abraxane
    Novel drug target Established target
    Trial Name AI-850

    PMIDs:
    23963862 17062688 17119350 16741658 16895478 17230521


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial TEND PharmGKB TTD

  • ERYTHROMYCIN   BCL2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17007374


    Sources:
    NCI

  • OXALIPLATIN   BCL2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977850


    Sources:
    ClearityFoundationBiomarkers NCI

  • TRETINOIN   BCL2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9402847


    Sources:
    NCI

  • DIETHYLSTILBESTROL   BCL2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15545218


    Sources:
    NCI

  • EPIRUBICIN   BCL2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14503796


    Sources:
    NCI

  • PENTOXIFYLLINE   BCL2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11836847


    Sources:
    NCI

  • ETOPOSIDE   BCL2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977850 11350408


    Sources:
    NCI

  • MITOXANTRONE   BCL2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11751483


    Sources:
    NCI

  • STREPTOZOCIN   BCL2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16741044


    Sources:
    NCI

  • CARBOPLATIN   BCL2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    ClearityFoundationBiomarkers PharmGKB

  • CISPLATIN   BCL2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12543810 11350408


    Sources:
    ClearityFoundationBiomarkers NCI

  • DOXORUBICIN   BCL2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16749867


    Sources:
    NCI

  • GOSSYPOL   BCL2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • VINCRISTINE   BCL2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • BORTEZOMIB   BCL2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • Ensembl: ENSG00000171791

    • Version: 101_38

    Alternate Names:
    BCL2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P10415

    • Version: January-2014

    Alternate Names:
    BCL2 Gene Symbol

    Gene Info:
    Target Class other
    Target Subclass regulator of apoptosis

    Publications:

  • RussLampel: ENSG00000171791

    • Version: 26-July-2011

    Alternate Names:
    APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415] Description
    ENSG00000171791 Ensembl Gene Id
    BCL2 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P10415

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000171791 Ensembl Gene Id
    596 Entrez Gene Id
    BCL2_HUMAN Uniprot Id

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Interpro Name Apoptosis regulator, Bcl-2, BH

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P10415

    • Version: 01-August-2011

    Alternate Names:
    596 Entrez Gene Id
    ENSG00000171791 Ensembl Gene Id
    P10415 Uniprot Accession

    Gene Info:
    Target Subclass Other
    Transmembrane Helix Count 1
    Target Main Class Other

    Publications:

  • PharmGKB: BCL2

    • Version: 18-August-2020

    Alternate Names:
    PA25302 PharmGKB ID

    Gene Info:

    Publications:
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
    Shaker OG et al., 2011, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients., Clin Chim Acta

  • CIViC: BCL2

    • Version: 14-September-2020

    Alternate Names:
    596 Entrez Gene ID
    59 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica
    Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov
    Blombery P et al., 2020, Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax., Blood

  • NCI: BCL2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Kuo et al., 1999, Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis., Mol. Pharmacol.
    Ran et al., 2005, [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]., Di Yi Jun Yi Da Xue Xue Bao
    Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.

  • DTC: BCL2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Abulwerdi FA et al., 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation., J Med Chem
    Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem

  • MyCancerGenome: BCL2

    • Version: 20-Jun-2017

    Alternate Names:
    BCL2 MyCancerGenome Gene Symbol
    BCL2 MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • ChemblInteractions: BCL2

    • Version: chembl_23

    Alternate Names:
    BCL2 GENE_SYMBOL
    Apoptosis regulator Bcl-2 UNIPROT

    Gene Info:

    Publications:

  • TALC: BCL-2

    • Version: 12-May-2016

    Alternate Names:
    BCL-2 Gene Symbol

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000171791

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000171791 Gene Symbol
    BCL2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: BCL2

    • Version: 11-November-2018

    Alternate Names:
    BCL2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Apoptosis regulator Bcl-2

    • Version: 2020.06.01

    Alternate Names:
    BCL-2 TTD Gene Abbreviation
    T31309 TTD Target ID

    Gene Info:

    Publications:

  • MskImpact: BCL2

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: BCL2

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: BCL2

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: BCL2

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: BCL2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21